Showing results (1081-1090 of 1,284) with videos related to

Sort By:
Pageof 129
Diabetes|March 1, 2005
Association testing of variants in the hepatocyte nuclear factor 4alpha gene with risk of type 2 diabetes in 7,883 peopleWendy Winckler, Robert R Graham, Paul I W de Bakker, et al.
The International Journal of Cardiovascular Imaging|October 9, 2025
CT coronary angiography in the lipid clinic: a pilot study and lipidologist surveyJohn Graby, James Sellek, Ali Khavandi, et al.
Journal of the American Chemical Society|May 27, 2020
Bioorthogonal Tetrazine Carbamate Cleavage by Highly Reactive <i>trans</i>-CycloocteneArthur H A M van Onzen, Ron M Versteegen, Freek J M Hoeben, et al.
Bioconjugate Chemistry|March 16, 2006
Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177LuHuma Mohsin, Fang Jia, Geethapriya Sivaguru, et al.
Frontiers in Ecology and Evolution|August 11, 2020
The Role of Vector Trait Variation in Vector-Borne Disease DynamicsLauren J Cator, Leah R Johnson, Erin A Mordecai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Cancer genomics: technology, discovery, and translationBen Tran, Janet E Dancey, Suzanne Kamel-Reid, et al.
Human Genetics|May 11, 2005
Anatomy of a founder effect: myotonic dystrophy in Northeastern QuebecVania Yotova, Damian Labuda, Ewa Zietkiewicz, et al.
American Journal of Human Genetics|May 23, 2000
Localization of a recessive gene for North American Indian childhood cirrhosis to chromosome region 16q22-and identification of a shared haplotypeC Bétard, A Rasquin-Weber, C Brewer, et al.
Protein Engineering|April 1, 1997
Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimerA A Kortt, M Lah, G W Oddie, et al.
The Patient|May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.
Pageof 129